

Cover Story
News Analysis
For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- No need for a speculum? A new era of HPV screening
- At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.” - Forty years after Chernobyl: Little evidence to show that radiation released from the accident increased cancers globally


















